Atossa Therapeutics, Inc.
ATOS Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$2.60
KIRA · Stoqly’s AI analyst, in plain words
- Atossa Therapeutics, Inc. lost $34.8M in fiscal 2025.
- Free cash flow was −$29.8M in fiscal 2025, — of revenue.
Market cap
$23.2M
P/E
—
Revenue
—
Net income
−$34.8M
Free cash flow
−$29.8M
Operating margin
—
Atossa Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$34.8M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Atossa Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 25, 2026
- Legal name
- ATOSSA THERAPEUTICS, INC.
- CIK
- 0001488039
Atossa Therapeutics, Inc. · ATOS
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$20.6M | −$27.0M | −$30.1M | −$25.5M | −$34.8M |
| Diluted EPS | −$0.18 | −$0.21 | −$0.24 | −$3.04 | −$4.04 |
| Cash | |||||
| Cash from operations | −$16.5M | −$20.8M | −$20.9M | −$21.0M | −$29.8M |
| Capital expenditure | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Free cash flow | −$16.5M | −$20.8M | −$21.0M | −$21.0M | −$29.8M |
| Share buybacks | — | $0.0M | $1.5M | $0.0M | — |
| Share count change | 935.4% | 108,125.7% | −0.4% | −93.3% | 2.6% |
| Debt and strength | |||||
| Cash and short-term investments | $136M | $111M | $88.5M | $71.1M | $41.3M |
| Shareholders' equity | $138M | $118M | $91.0M | $71.5M | $39.4M |
| Current ratio | 45.2x | 21.2x | 17.6x | 15.0x | 5.5x |
| Returns and quality | |||||
| Return on equity | −24.9% | −21.1% | −28.8% | −31.4% | −62.7% |
| Return on tangible equity | −14.9% | −22.9% | −33.1% | −35.7% | −88.4% |
| Altman Z'' | 48.9 | 22.6 | 15.7 | 9.6 | −12.0 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Atossa Therapeutics, Inc. · ATOS
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.60 a share, the company is worth $23.2M.
Source: SEC EDGAR XBRL filings (CIK 0001488039). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.